May 23, 2020 (Thomson StreetEvents) — Edited Transcript of Kaleido Biosciences Inc earnings conference call or presentation Thursday, May 14, 2020 at 12:30:00pm GMT
TEXT version of Transcript
================================================================================
Corporate Participants
================================================================================
* Alison Lawton
Kaleido Biosciences, Inc. – CEO, President & Director
* Amy Reilly
* Katharine Knobil
Kaleido Biosciences, Inc. – Chief Medical Officer and Head of Research & Development
* Michael W. Bonney
Kaleido Biosciences, Inc. – Executive Chair
================================================================================
Conference Call Participants
================================================================================
* Connor McGuinness Meehan
Morgan Stanley, Research Division – Research Associate
* Daniel G. Wolle
JP Morgan Chase & Co, Research Division – Analyst
* John Lawrence Newman
Canaccord Genuity Corp., Research Division – Principal & Senior Healthcare Analyst
* Samuel Lee
* Terence C. Flynn
Goldman Sachs Group Inc., Research Division – MD
================================================================================
Presentation
——————————————————————————–
Operator [1]
——————————————————————————–
Ladies and gentlemen, thank you for standing by, and welcome to Kaleido Biosciences Conference Call and Webcast. (Operator Instructions) I would also like to remind you that this call is being recorded for replay.
I would now like to turn the conference over to Amy Reilly, Kaleido Vice President of Communications and Investor Relations. Please go ahead.
——————————————————————————–
Amy Reilly, [2]
——————————————————————————–
Thank you, operator, and good morning, everyone. Welcome to Kaleido’s conference call and webcast. Two press releases from this morning and a short presentation relating to this call are available in the Investors and Media section of our website.
With me for today’s call are Mike Bonney, Executive Chair of Kaleido; Alison Lawton, President and Chief Executive Officer; Dr. Kate Knobil, Chief Medical Officer and Head of R&D; and Bill Duke, Chief Financial Officer. After our prepared remarks, we will open the call for questions.
Before we begin, let me remind you that on today’s call, we will be making forward-looking statements covered under the Private Securities Litigation Reform Act of 1995. These statements may involve risks and uncertainties that could cause actual results to differ from expectations and are described more fully in our filings with the SEC, which are also available on our website.
In addition, all forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date.
As you may be aware, Kaleido does not typically hold conference calls concurrent with quarterly financial results. However, given the number of topics to review today and their timing with quarter end, we decided this is the most appropriate forum for discussion. Going forward, we intend to host calls and webcast as appropriate based on news flow and clinical data.
I will now turn the call over to Kaleido’s Executive Chair, Mike Bonney.
——————————————————————————–
Michael W. Bonney, Kaleido Biosciences, Inc. – Executive Chair [3]
——————————————————————————–
Thank you, Amy, and good morning to everyone. First, our thoughts are with those affected by the COVID-19 pandemic, and we are grateful to all the health care workers and those that support them for their selfless efforts to support patients during this challenging time. It is important to note that the safety of patients, health care professionals and our employees remains our top priority during these trying times.
On the call this morning, Alison and Kate, our Chief Executive Officer and Chief Medical Officer and Head of R&D, respectively, will discuss one of the most exciting and compelling opportunities I’ve had the privilege to be part of in my nearly 40 years in the biopharmaceutical industry: the initiation of the COVID-19 clinical program utilizing our product candidate, KB109.
https://finance.yahoo.com/